D-0502

D-0502 is a small-molecule drug developed by InventisBio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: An oral selective estrogen receptor degrader (SERD) being developed for ER-positive, HER2-negative locally advanced or metastatic breast cancer, currently in a Phase III registrational trial. ClinicalTrials.gov describes the intervention as: * Dosage form: Tablet * Administration route: Oral, once a day. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer), in HR-positive / HER2-negative breast cancer. The largest, NCT06954961, plans to enrol 640 participants with primary completion expected 2026-11-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.